IVF · When IVF cycles do not succeed
Recurrent implantation failure — a structured approach when good embryos do not implant
Recurrent implantation failure (RIF) is the term used when multiple good-quality embryos fail to result in clinical pregnancy. The definition is not universally agreed, the causes are partly understood, and many of the proposed therapies have weak evidence behind them. This page describes a structured approach — what to investigate, what to treat, and what to avoid being over-tested for.
How RIF is defined
There is no single universally accepted definition. A practical working definition is the failure to achieve clinical pregnancy after the transfer of at least 4 good-quality embryos (cleavage or blastocyst) across a minimum of 3 fresh or frozen cycles in a woman under 40. Definitions vary; the principle is consistent — repeated failure despite morphologically good embryos and an apparently receptive endometrium.
Why definitions matter
Loose definitions of RIF lead to over-testing and over-treatment in patients who have simply had statistically expected outcomes. Many couples described as “RIF” after one or two failed transfers do not meet a meaningful clinical threshold. A structured work-up is reserved for true RIF, not for normal statistical variation.
Possible causes
- Embryo-related — chromosomal aneuploidy (the largest single cause), morphologically good but biologically poor embryos
- Endometrial — thin endometrium, polyps, fibroids distorting the cavity, adhesions, chronic endometritis
- Adenomyosis — an under-diagnosed cause
- Hydrosalpinx — tubal fluid that compromises implantation
- Endometriosis — particularly deep or extensive disease
- Thrombophilia — selected role; not all RIF patients need full thrombophilia screens
- Immune dysfunction — controversial and over-investigated in many clinics
- Lifestyle factors — BMI extremes, smoking, alcohol, untreated thyroid disease, vitamin deficiency
The structured work-up
- History review — prior cycles, embryo quality, embryo transfers, fertilisation methods, ovarian response, sperm parameters across cycles
- Saline-infusion sonohysterography or hysteroscopy — to exclude intrauterine pathology (polyps, fibroids, adhesions, septum)
- Endometrial biopsy with chronic endometritis screen — CD138 immunohistochemistry; treatable cause if positive
- MRI or detailed ultrasound — for adenomyosis and deep endometriosis
- Karyotype of both partners — balanced translocations
- Tubal evaluation — hydrosalpinx detection
- Targeted thrombophilia screen — antiphospholipid antibodies; broader thrombophilia testing only in selected cases
- Thyroid and prolactin
- Vitamin D, ferritin, HbA1c where indicated
- Sperm DNA fragmentation — selectively, particularly with male-factor history
Interventions with reasonable evidence
- Hysteroscopic removal of polyps, submucous fibroids, septae, adhesions
- Antibiotics for chronic endometritis — doxycycline or targeted antibiotic per culture
- Salpingectomy or proximal occlusion for hydrosalpinx before next transfer
- Optimisation of adenomyosis — GnRH agonist pre-treatment in selected cases
- PGT-A — in selected RIF cases, particularly with advanced maternal age
- Lifestyle correction — BMI, smoking, alcohol, thyroid status
- Low-dose aspirin and LMWH — selected use where antiphospholipid syndrome is established
Interventions with weak or no evidence
Several “RIF treatments” are widely advertised but have poor evidence:
- Intravenous immunoglobulin (IVIG) — not recommended outside research
- Intralipid infusion — not supported by good evidence
- Granulocyte colony-stimulating factor (G-CSF) — selected use; evidence mixed
- Endometrial scratching — evidence does not support routine use
- NK cell testing and immunomodulation — current consensus is that uterine NK testing is not clinically actionable
- Heparin in the absence of thrombophilia — not supported
- Embryo glue, embryo growth media additives — small to no clinical benefit
- ERA (endometrial receptivity array) — not supported as a routine investigation by current evidence
Patients are explicitly told what the evidence does and does not support, and offered the choice transparently.
When to consider alternatives
- Persistent failure despite full structured work-up and corrected modifiable factors
- Embryo quality limitations (advanced maternal age, declining reserve)
- Patient and couple values around continuing with own gametes or considering donor pathways
- The option to pause cycles and re-evaluate with fresh eyes
The institutional approach
This centre approaches RIF as a structured diagnostic problem rather than as a marketing opportunity. The work-up follows the evidence. Interventions with weak evidence are not pushed. Patients are told the truth about what is known and what is still uncertain. Where the underlying issue is embryo quality and time has run, the conversation about alternatives is opened gently and without pressure.
When to seek a second opinion
- After two or three failed transfers without a structured work-up
- If multiple add-ons are being recommended without evidence discussion
- If hysteroscopy or endometritis screen has not been done despite multiple failures
- If a clinic has not addressed hydrosalpinx, adenomyosis, or chronic endometritis as part of the plan
Guidelines we follow on this topic
- ESHRE Good Practice Recommendations on Repeated Implantation Failure
- ASRM committee opinion on RIF
- RCOG guidance on recurrent miscarriage and implantation failure
- Cochrane reviews on RIF interventions
Related reading
Dr. Priyadatt Patel
Senior Gynecologist · Advanced Laparoscopic Surgeon · IVF and Endometriosis Programme Lead
MS OBGyn · Pregnancy Care · Advanced Gynaecological Ultrasound · Fertility Preservation
ESHRE / ESGE / AAGL / ASRM guideline-aligned practice. 3D Karl Storz precision technique. Fertility-preservation-first philosophy. Evidence-based decisions, honest counselling, long-term outcomes orientation.
Science City Road, Ahmedabad 380060
Mon–Sat 11:00–20:00 · +91 97234 31544
Naranpura, Ahmedabad
Mon–Sat 08:30–10:30 · +91 70460 02566